Pelvic Health

Myovant and Pfizer Receive FDA Approval for MYFEMBREE, the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids

An estimated 5 million women in the U.S. suffer from symptoms of uterine fibroids, and an estimated 3 million women are inadequately treated by current medical therapy and require further treatment. Uterine fibroids are noncancerous tumors that develop in or on the muscular walls of the uterus and are among the most common reproductive tract tumors in women. In addition to an individual’s genetic…

Launched on Kickstarter: MERRI, a New Line of Lingerie to Combat UTIs

1 in 2 women will suffer from UTIs at some point in their life. And according to MERRI’s co-founders synthetic underwear is to blame. Gynecologists recommend wearing cotton underwear to prevent common infections such as thrush, but many women ignore this advice as the designs available are often considered frumpy or unflattering. And this is wehre MERRI comes in. MERRI have designed…

Evofem Receives Fast Track Designation for EVO100 for Prevention of Gonorrhea in Women

Evofem today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for EVO100 for the prevention of urogenital gonorrhea in women. Fast Track designation is designed to facilitate the development and expedite the review of new therapies to treat serious conditions and fill unmet medical needs. According to a new report published by the Centers for Disease…

Aspira Women’s Health Initiates Prospective Clinical Study for Benign Risk Monitoring and High Risk Early Ovarian Cancer Detection with Northwell Health

Aspira Women’s Health, a bioanalytical-based women’s health company focused on gynecologic disease and The Feinstein Institutes for Medical Research, the science arm of Northwell Health, the largest private Healthcare Provider in New York State, today announced the start of a prospective Clinical Study for Ovarian Cancer Risk Detection. Northwell Health treats over 2 million patients annually and employs over 16,000 credentialled physicians. The…

U.S. Reality TV Personality Cynthia Bailey-Hill Supports Reponsum, a New Fibroid App & Online Patient Community

Today, Real Housewives of Atlanta star Cynthia Bailey-Hill announced her support for Responsum for Fibroids, an online empowerment, knowledge, and support platform for women with uterine fibroids, a condition that affects 70-80% of all women by the age of 50. Provided in partnership with CARE About Fibroids and The White Dress Project—two of the nation’s leading fibroids support organizations—and underwritten with independent support from AbbVie, a global…

Roche Receives FDA Approval for the First Companion Diagnostic to Identify Endometrial Cancer Patients Eligible for Immunotherapy

Roche today announced U.S. Food and Drug Administration (FDA) approval of the VENTANA MMR RxDx Panel for advanced or recurrent endometrial cancer patients. MMR is a molecular mechanism that functions to correct certain errors that can spontaneously occur during DNA replication. Testing can identify patients eligible for treatment with JEMPERLI (dostarlimab-gxly) monotherapy, an anti-PD1 immunotherapy from GlaxoSmithKline (GSK) that was approved by…

UroMems Raises a $23M Series B to Fund Final Development of its Implantable Medical Device for Those Suffering from Urinary Incontinence

UroMems, developer and manufacturer of the electronic artificial urinary sphincter (eAUS), today announced that it has raised an additional €7 million in a second tranche of its previously announced Series B financing round completed in May 2020. The additional capital was provided by existing investors including Hil-Invent GmbH, Financière Arbevel, Wellington Partners, Bpifrance, via its FABS fund, Supernova Invest and btov Partners,…

Renovia Raises a $17M Series C for Its Pelvic Health Focused Digital Therapeutic leva

Renovia, a women-led company that develops digital therapeutics for female pelvic floor disorders, today announced the closing of an additional round of equity funding totaling $17 million. The financing included new investor, Parian Global Management, along with existing Renovia investors, including Perceptive Life Sciences, Longwood Fund, Ascension Ventures and OSF Ventures. “We’re very pleased to continue working with such an accomplished group of…